5.27% Jul 25, 08:38 PM
$2.56 Paid Quarterly
77.1% EPS $3.32
1 year Since 2013
11 days Aug 06, 2014

GSK - Upcoming Dividend Payouts
Next Ex-Dividend Date Aug 06

Amount Declare Date Ex-Dividend Date ▲ Record Date Pay Date Payout Type
$0.6482 2014-08-06 2014-08-08 2014-10-02 Regular
Date has passed
Next Ex-Dividend Date
Next Pay Date

GSK - Dividend Yield & Stock Price History
Current Dividend Yield 5.27%

Arrow-right
5y
All

GSK - Dividend Payout History
Current Annual Payout $2.56

5y
All
Dividend payouts are split-adjusted

GSK - Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
Reveal Dividend Growth History for GSK. 6.4% 3.9% 1 year
Annual dividend amounts based on Ex-dividend date

GSK - Historical Annual Dividend Data & Growth
Payouts Increasing For 1 year

Payout Amount Calendar Year Annual Growth
$2.4090 2013 3.9%
$2.3194 2012 5.2%

GSK - Historical Dividend Data
Payouts Increasing For 1 year

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$0.6482 2014-08-06 2014-08-08 2014-10-02 Unknown Regular Quarter
$0.6400 2014-05-14 2014-05-16 2014-07-10 Unknown Regular Quarter
$0.7496 2014-02-19 2014-02-21 2014-04-10 Unknown Regular Quarter
$0.6161 2013-11-13 2013-11-15 2014-01-09 Unknown Regular Quarter
$0.5532 2013-08-07 2013-08-09 2013-10-03 Unknown Regular Quarter

GlaxoSmithKline PLC (GSK) - News

  • Following news that UK-based GlaxoSmithKline plc (GSK) bribed doctors and officials to improve sales in China, the drugmaker announced that it...
  • GlaxoSmithKline to Sell Thrombosis Brands for $1.13B (GSK)

    GlaxoSmithKline plc (GSK) announced on Monday that it has agreed to sell its thrombosis drugs, Arixtra and Fraxiparine, and its Notre-Dame de Bondeville manufacturing facility for $1.13 billion. The British pharmaceutical company will sell both drug brands along with its manufacturing facility to The Aspen Group for £700 million or $1.13 billion in cash. This sale will allow GSK to focus on products with higher growth potential. GSK Chief Strategy Officer David Redfern commented: "Arixtra and Fraxiparine are established products that have consistently delivered strong revenues. However, our focus is on delivering an unprecedented late-stage pipeline and preparing for the launch of approved medicines. Aspen is a long-term partner of GSK and will be able to dedicate the resources that these products deserve to take them forward." GlaxoSmithKline shares were mostly flat during pre-market trading Monday. The stock is up 16% YTD.

    The Bottom Line

    Shares of GlaxoSmithKline plc (GSK) have a 4.38% yield based on Friday's closing price of $50.48. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • GlaxoSmithKline Upgraded to "Neutral" at JP Morgan (GSK)

    JP Morgan reported on Wednesday that it has upgraded healthcare company GlaxoSmithKline plc (GSK) . The firm has raised its rating on GSK to "Neutral" as analysts see upcoming catalysts balancing out risk. GlaxoSmithKline shares were up 29 cents, or 0.56%, during pre-market trading Wednesday. The stock is up 20% YTD. The Bottom Line Shares of GlaxoSmithKline plc (GSK) have a 4.25% yield based on Tuesday's closing price of $52.01. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • JP Morgan Gets Bearish on GlaxoSmithKline; Says 2013 Earnings are at Risk (GSK)

    U.K.-based pharmaceutical giant GlaxoSmithKline plc (GSK) on Wednesday caught a big downgrade from analysts at JP Morgan. The firm slashed its rating on GSK from "Neutral" to "Underweight," noting worries about the company's upcoming earnings. A JP Morgan analyst commented, "With material risk to 2013 earnings, no imminent positive catalysts, and almost no upside to our new PT, we downgrade to Underweight. GSK is entering an investment phase. After reassessing the investment required to execute on the pipeline, already taken for granted by consensus, we now expect Operating margins to contract, rather than expand in 2013, and we now forecast a 2013 Operating margin 200bps below consensus. We see earnings risk in 2013, with material Operating profit and earnings growth unlikely for at least a year further out than is currently forecast by consensus (which expects topline growth and margin expansion in 2013)." GlaxoSmithKline shares fell 53 cents, or -1.2%, in premarket trading Wednesday. The Bottom Line Shares of GlaxoSmithKline plc (GSK) have a 4.78% dividend yield, based on last night's closing stock price of $46.07. The stock has technical support in the $43-$44 price area. If the shares can firm up, we see overhead resistance around the $48-$50 price levels. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Acuity Brands...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Deutsche Bank...
  • FDA Approves GlaxoSmithKline's Lupus Treatment (GSK)

    British pharmaceutical giant GlaxoSmithKline plc (GSK) got some welcome news from the FDA late Wednesday night, as the federal regulator approved a lupus treatment drug that GSK has been pegged to market. The drug, called Benlysta, was developed by U.S.-based Human Genome Sciences (HGSI) and will be marketed and sold by GSK. Benlysta is the first lupus treatment drug approved in the U.S. since 1955. Lupus, a potentially fatal autoimmune disease, affects 1.5 million Americans and 5 million people worldwide, according to the Lupus Foundation of America. GlaxoSmithKline shares rose 20 cents, or +0.5%, in premarket trading Thursday. The Bottom Line Shares of GlaxoSmithKline (GSK) have a 6.38% dividend yield, based on last night's closing stock price of $38.58. The stock has technical support in the $36 price area. If the shares can firm up, we see overhead resistance around the $40-$42 price levels. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

    Expand to read the full story »

  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Beckman Coulter...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Diamond Offshore...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights TC Pipelines L.P....
Top-5-pitch